Cabaletta Extends Cash Runway Into 1Q28 With $299.4M, Starts Second Registrational Study
CABA is trading near its 52-week low of $1.32 (12% above the low).
Summary
Cabaletta ended September with $299.4M in cash, up from $133.6M at year-end, and now says that funds the operating plan into 1Q28 — a meaningful extension for a company that carried a going concern warning in its Q2 10-Q. The quarter itself was a wider loss, $53.1M versus $44.9M a year ago, with R&D at $47.1M, though the net loss came in slightly better than analyst expectations. The bigger news is clinical: the RESET-Myositis registrational topline is now guided to 2H27 with a BLA in 1Q28, and the company initiated its second registrational cohort, RESET-SSc, in systemic sclerosis-ILD patients. Management said enrollment in the adult myositis study picked up in recent weeks after a slow 3Q26 that it attributes to patient and physician caution following safety events reported by others in the field. One-year dermatomyositis and up-to-two-year lupus nephritis durability data, plus updated RESET safety data, are due at ACR Convergence, with the oral presentation on November 8 and posters on November 9.
At the time of this announcement, CABA was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $240.8M. The 52-week trading range was $1.32 to $4.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.